Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
about
Pharmacological treatment for depression during opioid agonist treatment for opioid dependenceTricyclic antidepressant pharmacology and therapeutic drug interactions updatedRasagiline - a novel MAO B inhibitor in Parkinson's disease therapyPrime Drug Interplay in Dental PracticeRevisiting the monoamine hypothesis of depression: a new perspectiveComputational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanismsAdverse safety events in patients with Chronic Kidney Disease (CKD).Psychotherapeutic benefits of opioid agonist therapy.Current place of monoamine oxidase inhibitors in the treatment of depression.MAOIs - does the evidence warrant their resurrection?Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats.Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists.[Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.Serotonin: a review.Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants.Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorderInhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicityPain management in patients with chronic kidney disease.Registered nurse-administered sedation for gastrointestinal endoscopic procedure.A review of opioid prescription in a teaching hospital in Colombia.Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humansSedation and monitoring for gastrointestinal endoscopy.Dextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability.Linezolid is associated with serotonin syndrome in a patient receiving amitriptyline, and fentanyl: a case report and review of the literatureZydis selegiline in the management of Parkinson's disease.Postherpetic neuralgia: epidemiology, pathophysiology and management.Management of acute and post-operative pain in chronic kidney disease.Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trialTramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice.Bath salts: a newly recognized cause of acute kidney injury.Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine.CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review.Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.Safety of rasagiline for the treatment of Parkinson's disease.Pharmacologic safety concerns in Parkinson's disease: facts and insights.Serotonin syndrome: take a closer look at the unwell surgical patient.
P2860
Q24235458-20B7A27E-46D7-49AD-9F56-DBAEA04871C4Q24564967-E41A172E-1505-4FCD-B304-FC9381097EEDQ24654614-02BEBCAB-625E-4B84-ADC3-CCCB1ECA7C94Q26748474-F7E3AA7E-4759-4956-8453-7466C41C36C8Q28660308-C4B354C4-AA07-448B-BDCD-88873F679B54Q28730803-B813AD3A-4027-4CCA-851B-0866971459A0Q30245199-C9909910-A310-42C4-B64C-D08993DBAA94Q34014407-880AF2FB-194E-4800-8A85-634FA9C08850Q34363276-38D78362-0719-4A27-824E-1AA07076ECB6Q34515817-77E9F9D0-E2AB-40CE-AE56-9524ECF04041Q34564534-14D62C4D-DD1D-4AED-8A1B-7286E3652973Q34584411-2F2E8D99-BB2A-4A31-9AA2-399A4A04F6C9Q34636179-E884A2D5-6CCA-4E84-B070-D13B339CCFEDQ34647657-D684EE5B-6910-4631-B294-10C15E2BACEBQ34777881-6FA139DC-9383-4E9D-8025-95A273E0B9CBQ34867111-28ABF6BF-242F-4B9B-AC79-121260F54063Q34867700-B940B5FF-5D58-4434-B264-592BAAC93A03Q35002576-03592380-5A8F-4AFD-A5E6-F18047C975E3Q35109208-5FD20EF0-0726-4F1D-B05B-3CE62338F584Q35573940-A2645F78-2D59-466F-B875-EF9B32C75817Q35850792-6B4BF5F4-8815-425B-AFCA-1ECD0DF19981Q36235096-4ED0D978-7629-49B0-87D0-1188B2182B78Q36582359-A8BCAD2C-465A-4AC2-B8DD-4286CCB90938Q36616023-E6FDEDF9-F798-4904-AE4E-ED34825D84EBQ36675422-78D85618-04FB-4372-9759-ECFC7DCBF0D4Q36702836-2A8B1803-49FD-4781-AE19-7DF303941F09Q36968199-F6A9439E-EAF7-46EB-8D3E-930A5DC59BA0Q36998853-74370D5C-4315-4B64-888E-9FA8D3956B68Q37119294-2C93BDBB-0EAE-4829-9E49-6513A4FCCCDBQ37164044-38083A01-2FFF-4200-A323-341F195122ECQ37360140-ED094838-8515-4E67-8F0C-FEBB94C32366Q37556263-77A16515-7090-468E-BE98-A1042C64C395Q37656983-4929031C-8FA7-49F0-B6FD-FD1746E58D9BQ37689364-0AA57496-0950-4B75-AFD1-A0F8F6651701Q37807282-76B687B0-D9D1-4BF9-85FB-D83608C5B446Q37822823-15FEB71E-80F3-44DD-B523-6A6AD464D8EDQ37830040-D688CC26-46FB-4919-85C6-32B241B4DA6DQ37859776-35460BB3-ED89-433C-9A14-D12552EDE622Q37950427-1AD14E7D-746F-4FFC-A782-5DE9CF1BFB88Q37951236-CC920A1E-106F-49DE-A119-495C92506251
P2860
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@ast
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@en
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@nl
type
label
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@ast
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@en
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@nl
prefLabel
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@ast
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@en
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@nl
P356
P1476
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
@en
P2093
P K Gillman
P304
P356
10.1093/BJA/AEI210
P407
P577
2005-10-01T00:00:00Z